Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma
Mast cells are a major component of the immune microenvironment in tumour tissues and modulate tumour progression by releasing pro‐tumorigenic and antitumorigenic molecules. Regarding the impact of mast cells on the outcomes of patients with lung adenocarcinoma (LUAD) patient, several published stud...
Main Authors: | Xuanwen Bao, Run Shi, Tianyu Zhao, Yanfang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-05-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12670 |
Similar Items
-
Identifying and Validating Potential Biomarkers of Early Stage Lung Adenocarcinoma Diagnosis and Prognosis
by: Yingji Chen, et al.
Published: (2021-04-01) -
CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients
by: Yanwei Zhang, et al.
Published: (2020-06-01) -
An individualized immune prognostic signature in lung adenocarcinoma
by: Liangdong Sun, et al.
Published: (2020-05-01) -
Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy
by: Xiaodong Yang, et al.
Published: (2021-06-01) -
Identification of an Individualized Metabolism Prognostic Signature and Related Therapy Regimens in Early Stage Lung Adenocarcinoma
by: Junjie Hu, et al.
Published: (2021-04-01)